Clearbridge Health to list on Catalist; seeking to raise $24.6 million

Clearbridge Health to list on Catalist; seeking to raise $24.6 million

Benjamin Cher
11/12/17, 05:15 pm

SINGAPORE (Dec 11): Clearbridge Health has announced an initial public offering to list on the Singapore Exchange (SGX) Catalist Board with an invitation issue of 88 million shares at 28 cents each, to raise $24.6 million.

This issue represents approximately 18.3% of the enlarged share capital of 481 million shares of Clearbridge, bringing its market capitalisation post listing to approximately $134.7 million.

Clearbridge formerly ran an accelerator programme to incubate and accelerate healthcare technology start-ups, managing a $40 million fund to invest in life-sciences companies under the SPRING Singapore Biomedical Sciences Accelerator programme, before pivoting and renaming itself Clearbridge Health.

The company’s business comprises of three segments: laboratory testing services, medical clinics, and strategic equity participation in precision medical technology companies.

Jeremy Yee, chief executive officer and executive director of Clearbridge Health, was a former chief executive officer of Cordlife. The senior management of Clearbridge were also formerly from Cordlife.

“We aim to promote precision healthcare in Asia, by empowering patients with greater access to health information and increasing patient survival by taking advantage of best-in-class technologies and workflows to provide a wide range of better purpose-suited products and services,” says Yee in a statement on Monday.

The company hopes to leverage on Singapore’s status as a medical tourism hub for a ready supply of patients, as well as the growing demand for healthcare around the region.

Clearbridge intends to grow its medical clinics and centres in Asia, and has already entered into a term sheet agreement to potentially acquire a medical centre in the Philippines.

The company also intends to collaborate to market new medical technologies and expand its laboratory testing services business organically or inorganically. 

Of the proceeds, $11 million has been earmarked for expanding medical clinics and centres, while $3 million has been allocated to expanding the laboratory testing services.  The proceeds will also be used for working capital and general corporate purposes.

“There is huge potential for greater adoption of precision medicine in Singapore and around the region,” says Yee. “The listing will serve as a platform for the group to grow our comprehensive suite of healthcare services.”

“We will continue to look for suitable opportunities to grow our network of medical clinics and centres, while expanding and strengthening our market position in laboratory testing services. We will also continue to invest and pursue breakthroughs in promising medical technologies that will position us as the leading healthcare player for the future,” he adds.

The invitation will close at 12 noon on Dec 14, with trading expected to commence at 9am on Dec 18.

Right timing: STI stays intact, but Hong Fok is at extreme overbought high

SINGAPORE (Mar 23): Although quarterly momentum appears ambivalent as it is consolidating beneath its own moving average, prices are intact. They have established support at the confluence of the 50- and 200-day moving averages which are moving into an increasingly positive stance at 3,217 and 3,186 respectively. The index may well be able to regain its 50-day moving average as short term stochastics is turning up from the bottom of its range. Since medium term indicators are neutral and drifting sideways, short term indicators could keep the STI afloat. However the range is likely to be ....

EY Singapore launches 18th edition of Entrepreneur Of The Year awards

SINGAPORE (Mar 22): The search has started for the 18th EY Entrepreneur Of The Year, as part of the bid to promote entrepreneurship and shape a new role model for the business community. Ernst & Young LLP, organiser of the annual awards, observes that entrepreneurs in Singapore, and the world, have built some of the world’s most enduring companies. The businesses they build don’t just create employment and contribute to the GDP. “Their creativity, tenacity and courage serve as an inspiration for many. In many ways, the way they overcome the odds, the power of their influence, a....

Challenger Tech's 2.94% shareholder says offer price too low, calls for higher dividend payouts

SINGAPORE (Mar 22): Pangolin Investment Management, which holds a 2.94% stake in Challenger Technologies through its Pangolin Asia Fund, is calling on other shareholders to reject Digileap Capital’s delisting offer at the company’s upcoming EGM.   Pangolin says the offer price of 56 cents per share, which translates to a price-to-earnings ratio of 9.9 times, is too low and thus unfair to minority shareholders. In a letter sent to The Edge Singapore on Friday, Pangolin explains its reasons for strongly advising other Challenger shareholders to reject the offer, which it deems “....